151 related articles for article (PubMed ID: 11042239)
1. Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry.
Shah MR; Granger CB; Bart BA; McMurray JJ; Petrie MC; Michelson EL; Tudor GE; Swedberg K; Stevenson LW; Califf RM; Pfeffer MA
Am J Med; 2000 Oct; 109(6):489-92. PubMed ID: 11042239
[No Abstract] [Full Text] [Related]
2. Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE).
Al-Zakwani I; Sulaiman K; Al-Lawati JA; Alsheikh-Ali AA; Panduranga P; Al-Habib KF; Al Suwaidi J; Al-Mahmeed W; Al-Faleh H; Elasfar A; Al-Motarreb A; Ridha M; Bulbanat B; Al-Jarallah M; Bazargani N; Asaad N; Amin H
Curr Vasc Pharmacol; 2018; 16(6):596-602. PubMed ID: 28820057
[TBL] [Abstract][Full Text] [Related]
3. Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Kumar A; Aronow WS; Vadnerkar A; Sivan K; Mittal S
Am J Ther; 2009; 16(1):5-7. PubMed ID: 19142162
[TBL] [Abstract][Full Text] [Related]
4. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study.
Echemann M; Zannad F; Briançon S; Juillière Y; Mertès PM; Virion JM; Villemot JP
Am Heart J; 2000 Apr; 139(4):624-31. PubMed ID: 10740143
[TBL] [Abstract][Full Text] [Related]
5. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.
Bart BA; Ertl G; Held P; Kuch J; Maggioni AP; McMurray J; Michelson EL; Rouleau JL; Warner Stevenson L; Swedberg K; Young JB; Yusuf S; Sellers MA; Granger CB; Califf RM; Pfeffer MA
Eur Heart J; 1999 Aug; 20(16):1182-90. PubMed ID: 10448027
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of heart failure: implications of the recent European Society of Cardiology Guidelines for the older patient.
Gillespie ND; McMurdo ME; Struthers AD
Age Ageing; 2003 Nov; 32(6):563-5. PubMed ID: 14599994
[No Abstract] [Full Text] [Related]
7. Is the optimal dose of angiotensin-converting enzyme inhibitors in patients with congestive heart failure definitely established?
Delahaye F; de Gevigney G
J Am Coll Cardiol; 2000 Dec; 36(7):2096-7. PubMed ID: 11127446
[No Abstract] [Full Text] [Related]
8. Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
Thanikachalam S; Manchanda SC
Indian Heart J; 2003; 55(2):167-71. PubMed ID: 12921333
[TBL] [Abstract][Full Text] [Related]
9. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
Azizi M; Ménard J
Circulation; 2004 Jun; 109(21):2492-9. PubMed ID: 15173039
[No Abstract] [Full Text] [Related]
10. [Drug therapy in chronic heart failure].
Airaksinen J; Luomanmäki K
Duodecim; 1997; 113(10):965-71. PubMed ID: 11466831
[No Abstract] [Full Text] [Related]
11. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
12. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure.
Thornton PL; Ahmed A
J Am Coll Cardiol; 2004 Apr; 43(7):1333; author reply 1333-4. PubMed ID: 15063454
[No Abstract] [Full Text] [Related]
14. [New prospects in diagnosis and treatment of heart failure].
Pfister U; Lerch R; Hess OM
Praxis (Bern 1994); 2002 Jan; 91(5):177-80. PubMed ID: 11865776
[No Abstract] [Full Text] [Related]
15. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction.
Aronow WS; Ahn C; Kronzon I
Am J Cardiol; 2001 Dec; 88(11):1298-300. PubMed ID: 11728359
[No Abstract] [Full Text] [Related]
16. A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction.
Abdulla J; Abildstrom SZ; Christensen E; Kober L; Torp-Pedersen C
Eur J Heart Fail; 2004 Dec; 6(7):927-35. PubMed ID: 15556055
[TBL] [Abstract][Full Text] [Related]
17. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
Knight EL; Glynn RJ; McIntyre KM; Mogun H; Avorn J
Am Heart J; 1999 Nov; 138(5 Pt 1):849-55. PubMed ID: 10539815
[TBL] [Abstract][Full Text] [Related]
18. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study.
Gattis WA; Hasselblad V; Whellan DJ; O'Connor CM
Arch Intern Med; 1999 Sep; 159(16):1939-45. PubMed ID: 10493325
[TBL] [Abstract][Full Text] [Related]
19. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors.
Philbin EF; Rocco TA; Lindenmuth NW; Ulrich K; Jenkins PL
Am J Med; 2000 Dec; 109(8):605-13. PubMed ID: 11099679
[TBL] [Abstract][Full Text] [Related]
20. Sudden cardiac death after heart failure; symptomatic versus disease treatment? An editorial comment.
Buckberg GD;
Heart Fail Rev; 2004 Oct; 9(4):347-51. PubMed ID: 15886980
[No Abstract] [Full Text] [Related]
[Next] [New Search]
